CMO helps TxCell move forward with clinical supplies after pilot plant closed

TxCell, a French biotech working on T cell treatments for chronic inflammatory and autoimmune diseases, says that Belgian CMO MaSTherCell has successfully completed manufacturing validation runs of its lead drug candidate Ovasave. TxCell contracted with the CMO after French authorities last year shut down its own pilot plant in Besançon because of sterility concerns. The company said it has submitted to authorities amendments to its clinical protocol and expects this will allow it to resume its clinical study of Ovasave. Release | More

Suggested Articles

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.